Momenta Pharmaceuticals Inc
Teva’s Copaxone Maintains Market Share amid Intense Competition
In fiscal 1Q18, Teva (TEVA) reported sales of $645 million for its multiple sclerosis drug, Copaxone, a sequential decline of ~21%.
How Did Sandoz Perform in 4Q17 and Fiscal 2017?
In 4Q17, Novartis’s (NVS) subsidiary Sandoz reported revenues of $2.6 billion.
A Look at Teva Pharmaceutical’s Fiscal 2018 Sales Guidance
Teva Pharmaceutical (TEVA) provided fiscal 2018 guidance during its fiscal 2017 earnings release on February 8, 2018.
Regeneron Pharmaceuticals and Its Financial Performance
Regeneron Pharmaceuticals (REGN) generated total revenues of $5.8 billion in fiscal 2017 compared with $4.8 billion in fiscal 2016.
A Look at Regeneron Pharmaceuticals’ Product Pipeline
Regeneron Pharmaceuticals (REGN) currently has 15 products in clinical development.
Mylan’s Recent Commercial and Product Developments
Mylan’s recent commercial developments include the acquisition of the Cold-EEZE brand from ProPhase Labs and the acquisition of Meda AB.
The Biotechnology Industry and Multiple Sclerosis Therapies
Most multiple sclerosis drugs are very costly at about $55,000 per year. The FDA’s April 2015 approval of a generic version of Copaxone is expected to lower the overall price of the therapy.
Why Teva’s Specialty Medicines Performance Declined in 1Q15
Teva’s new drug application for ProAir RespiClick was approved, with an expected launch of 2Q15. ProAir is the first breath-actuated dry-powder inhaler used to treat acute asthma symptoms.